All data are based on the daily closing price as of December 24, 2024
s
SanBio
4592.TSE
4.73 USD
-0.10
-2.07%
Overview
Last close
4.73 usd
Market cap
324.80M usd
52 week high
9.45 usd
52 week low
2.57 usd
Target price
7.2 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3458.1885
Price/Book Value
87.0651
Enterprise Value
331.96M usd
EV/Revenue
3405.5195
EV/EBITDA
-9.0194
Key financials
Revenue TTM
146496.82 usd
Gross Profit TTM
2.85M usd
EBITDA TTM
-19.21M usd
Earnings per Share
-0.2 usd
Dividend
N/A usd
Total assets
23.60M usd
Net debt
-16.91M usd
About
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.